Cargando…

Canakinumab (ACZ885, a fully human IgG1 anti-IL-1β mAb) induces sustained remission in pediatric patients with cryopyrin-associated periodic syndrome (CAPS)

INTRODUCTION: Cryopyrin-associated periodic syndrome (CAPS) represents a spectrum of three auto-inflammatory syndromes, familial cold auto-inflammatory syndrome (FCAS), Muckle-Wells syndrome (MWS), and neonatal-onset multisystem inflammatory disease/chronic infantile neurological cutaneous and artic...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kuemmerle-Deschner, Jasmin B, Ramos, Eduardo, Blank, Norbert, Roesler, Joachim, Felix, Sandra D, Jung, Thomas, Stricker, Kirstin, Chakraborty, Abhijit, Tannenbaum, Stacey, Wright, Andrew M, Rordorf, Christiane
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2011
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3241378/ https://www.ncbi.nlm.nih.gov/pubmed/21356079 http://dx.doi.org/10.1186/ar3266

Ejemplares similares

12.4 ACZ885 (canakinumab), a new IL-1 beta blocking monoclonal antibody provides long-lasting remission in children with cryopyrin associated periodic syndrome (CAPS)
por: Kümmerle-Deschner, J, et al.
Publicado: (2008)

The phagocyte specific protein S100A12 as a novel biomarker in Muckle-Wells-Syndrome before and during therapy with Anakinra and Canakinumab (ACZ885)
por: Wittkowski, H, et al.
Publicado: (2008)

A refractory heterogeneous Cryopyrin-Associated Periodic Syndrome (CAPS) phenotype related to V198M mutation responds to canakinumab - a case report
por: Hansmann, Sandra, et al.
Publicado: (2011)

Long-term safety and efficacy of Canakinumab in cryopyrin-associated periodic syndrome (CAPS) patients: results from beta-confident registry
por: Kuemmerle-Deschner, J, et al.
Publicado: (2015)

Diagnosis and Management of the Cryopyrin-Associated Periodic Syndromes (CAPS): What Do We Know Today?
por: Welzel, Tatjana, et al.
Publicado: (2021)

Dosing patterns of canakinumab in patients with Cryopyrin-Associated Periodic Syndromes (CAPS): A comparative analysis of a study in Western versus Japanese patients
por: Bader-Meunier, B, et al.
Publicado: (2011)

Rapid and Sustained Long‐Term Efficacy and Safety of Canakinumab in Patients With Cryopyrin‐Associated Periodic Syndrome Ages Five Years and Younger
por: Brogan, Paul A., et al.
Publicado: (2019)

PW02-041 - Canakinumab treatment regimens in CAPS-patients
por: Hofer, F, et al.
Publicado: (2013)

PReS-FINAL-2224: Canakinumab treatment regimens in CAPS-patients
por: Hofer, F, et al.
Publicado: (2013)

2.2 A phase II trial with canakinumab, a new IL-1beta blocking monoclonal antibody (ACZ885), to evaluate preliminary dosing, safety and efficacy profile in children with systemic Juvenile Idiopathic arthritis (sJIA)
por: Ruperto, N, et al.
Publicado: (2008)

Long-term safety and effectiveness of canakinumab therapy in patients with cryopyrin-associated periodic syndrome: results from the β-Confident Registry
por: Walker, Ulrich A, et al.
Publicado: (2021)

Sustained remission of symptoms and improved health-related quality of life in patients with cryopyrin-associated periodic syndrome treated with canakinumab: results of a double-blind placebo-controlled randomized withdrawal study
por: Koné-Paut, Isabelle, et al.
Publicado: (2011)

Critical appraisal of canakinumab in the treatment of adults and children with cryopyrin-associated periodic syndrome (CAPS)
por: Toker, Ori, et al.
Publicado: (2010)

Canakinumab treat-to target strategies increase complete response rate in CAPS
por: Kuemmerle-Deschner, J, et al.
Publicado: (2015)

An experience of use of canakinumab IL-1 inhibitor in children with cryopyrin-associated periodic syndromes (CAPS)
por: Salugina, Svetlana O, et al.
Publicado: (2014)

Canakinumab in the routinary clinical practice in cryopyrin-associated periodic syndromes (CAPS): one year of follow-up
por: Caorsi, R, et al.
Publicado: (2011)

Pharmacokinetics of Canakinumab in children younger than 2 years old with CAPS
por: Kalabus, J, et al.
Publicado: (2015)

The human anti-IL-1β monoclonal antibody ACZ885 is effective in joint inflammation models in mice and in a proof-of-concept study in patients with rheumatoid arthritis
por: Alten, Rieke, et al.
Publicado: (2008)

Efficacy, safety, and post-vaccination antibody titer data in children with CAPS treated with Canakinumab
por: Brogan, P, et al.
Publicado: (2015)

β-Confident-registry: aiming to be largest-ever studied cohort of cryopyrin-associated periodic syndromes (CAPS) patients. Study design and baseline characteristics
por: Kuemmerle-Deschner, J, et al.
Publicado: (2011)

Pharmacokinetic and Pharmacodynamic Properties of Canakinumab, a Human Anti-Interleukin-1β Monoclonal Antibody
por: Chakraborty, Abhijit, et al.
Publicado: (2012)

Evidence based recommendations for diagnosis and treatment of cryopyrin-associated periodic syndromes (CAPS)
por: Haar, Nienke Ter, et al.
Publicado: (2014)

The schedule of administration of canakinumab in cryopyrin associated periodic syndrome is driven by the phenotype severity rather than the age
por: Caorsi, Roberta, et al.
Publicado: (2013)

National CAPS (Cryopyrin-Associated Periodic Syndrome) Registry
por: Bibalo, C, et al.
Publicado: (2011)

Rilonacept in the management of cryopyrin-associated periodic syndromes (CAPS)
por: Gillespie, Justin, et al.
Publicado: (2010)

Methodological challenges in monitoring new treatments for rare diseases: lessons from the cryopyrin-associated periodic syndrome registry
por: Tilson, Hugh, et al.
Publicado: (2013)

Live‐attenuated vaccines in a cryopyrin‐associated periodic syndrome patient receiving canakinumab treatment during infancy
por: Watanabe, Misa, et al.
Publicado: (2017)

Systematic literature review of efficacy/effectiveness and safety of current therapies for the treatment of cryopyrin-associated periodic syndrome, hyperimmunoglobulin D syndrome and tumour necrosis factor receptor-associated periodic syndrome
por: Kuemmerle-Deschner, Jasmin Beate, et al.
Publicado: (2020)

Neurological outcome of patients with cryopyrin-associated periodic syndrome (CAPS)
por: Mamoudjy, Nafissa, et al.
Publicado: (2017)

Decreased quality of life and societal impact of cryopyrin-associated periodic syndrome treated with canakinumab: a questionnaire based cohort study
por: Mulders-Manders, Catharina M., et al.
Publicado: (2018)

The genetic and clinical characteristics and effects of Canakinumab on cryopyrin-associated periodic syndrome: a large pediatric cohort study from China
por: Shu, Zhou, et al.
Publicado: (2023)

P02-027 - Quality of life in CAPS treated by Canakinumab
por: Marsaud, C, et al.
Publicado: (2013)

Unmet psychosocial needs in CAPS
por: Erbis, G, et al.
Publicado: (2015)

A Retrospective Patient Chart Review and Survey in Patients with Cryopyrin-associated Periodic Syndromes Treated with Anakinra
por: Lachmann, Helen J., et al.
Publicado: (2013)

Increasing the Interval of Canakinumab Administration Effectively Supports the Remission of Schnitzler's Syndrome
por: Gorodetskiy, Vadim R., et al.
Publicado: (2018)

Retrospective case series describing the efficacy, safety and cost-effectiveness of a vial-sharing programme for canakinumab treatment for paediatric patients with cryopyrin-associated periodic syndrome
por: Elmi, Abdulkadir A., et al.
Publicado: (2019)

In vivo regulation of interleukin 1β in patients with cryopyrin-associated periodic syndromes
por: Lachmann, Helen J., et al.
Publicado: (2009)

Cryopyrin-associated periodic syndromes (CAPS): report on two cases (Muckle-Wells syndrome (MWS) and CINCA/NOMID)
por: Salugina, SO, et al.
Publicado: (2011)

Long term management of patients with cryopyrin-associated periodic syndromes (CAPS): focus on rilonacept (IL-1 Trap)
por: Church, Leigh D, et al.
Publicado: (2008)

PReS-FINAL-2241: Cases of cryopyrin-associated periodic syndromes (CAPS) in one single rheumatologic center of Russia
por: Salugina, SO, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_9gdeg8f8qh9oqlj7kabekgkuo6